明月镜片股份有限公司 2024 年度董事会工作报告 2024 年度，明月镜片股份有限公司（以下简称"公司"）董事会严格遵守 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）等法律法规，规范运作，科学决策，严格履行《明月 镜片股份有限公司章程》（以下简称"《公司章程》"）赋予的各项职责，认真贯 彻股东大会的各项决议。全体董事恪尽职守、勤勉尽责，切实保障公司及全体 股东的利益。现将董事会 2024 年度的主要工作报告如下： 报告期内，公司实现营业收入 77,029.78 万元，同比增长 2.88%；归属于上 市公司股东的净利润 17,678.59 万元，同比上升 12.21%。 二、董事会日常工作情况 （一）董事会会议召开情况 报告期内，公司董事会严格遵守《深圳证券交易所创业板股票上市规则》、 《公司章程》及相关法律法规的规定，对公司相关事项做出决策，程序合法合 规，全年董事会共召开会议 6 次，审议议案 29 项，具体如下： | No. | 召开日期 | 届次 | 审议议案 | | --- | --- | --- | --- | | 1 | 2024/1/ ...

非经营性资金占用及其他关联资金 往来情况的专项报告 明月镜片股份有限公司 二○二四年度 关于明月镜片股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZK10137 号 明月镜片股份有限公司全体股东： 我们审计了明月镜片股份有限公司(以下简称"明月镜片")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表、2024 年度合并及母公司利润表、合并及母公司现金流量表、合 并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 16 日出具了报告号为信会师报字[2025]第 ZK10136 号的无保留意 见审计报告。 中国注册会计师： 明月镜片管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理》的相关规定编制了后附的 2024 年度非经营 性资金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是明月镜片管理层的责任。 ...

根据公司及子公司经营发展的需要，为更好地支持公司及子公司业务拓展， 公司董事会同意公司及子公司 2025 年度向银行等金融机构申请不超过人民币 5 亿元的综合授信额度。授信内容包括但不限于流动资金贷款、银行承兑汇票（含 一年期电票）、开立国内外信用证、商票保贴、进口押汇、非融资性保函等综合 业务。以上授信额度不等于公司及子公司的实际融资金额，实际融资金额应在授 信额度内，并以银行与公司及子公司实际发生的融资金额为准，具体融资金额将 视公司及子公司运营资金的实际需求来合理确定。 授权有效期自公司 2024 年年度股东大会审议通过之日起至 2025 年年度股 东大会召开之日止，授信期内，该等授权额度在授权范围及有效期内可循环使用。 证券代码：301101 证券简称：明月镜片 公告编号：2025-007 明月镜片股份有限公司 关于公司及子公司 2025 年度向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开了第 二届董事会第十七次会议，审议通过了《关于公司及子公 ...

证券代码：301101 证券简称：明月镜片 公告编号：2025-012 明月镜片股份有限公司 关于召开公司 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开的第 二届董事会第十七次会议审议通过了《关于召开公司 2024 年年度股东大会的议 案》，决定于 2025 年 5 月 13 日（星期二）14:30 召开 2024 年年度股东大会，现 将有关事项通知如下： 一、会议召开的基本情况 （一）会议届次：2024 年年度股东大会 （二）会议召集人：董事会。公司第二届董事会第十七次会议于 2025 年 4 月 16 日召开，审议通过了《关于召开公司 2024 年年度股东大会的议案》，同意 召开本次股东大会。 （三）会议召开的合法性及合规性：本次董事会召开股东大会会议符合有关 法律、行政法规、部门规章、规范性文件和《公司章程》的相关规定。 （四）会议召开日期、时间： 1、会议召开时间：2025 年 5 月 13 日（星期二）14:30 2、网络投票时间：202 ...

证券代码：301101 证券简称：明月镜片 公告编号：2025-003 明月镜片股份有限公司 第二届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届监事会第十七次会议于 2025 年 4 月 16 日在公司会议室以现场表决方式召开。本次会议通知于 2025 年 4 月 4 日以专人送达、电话、微信等形式通知了全体监事。本次会议由监事会主 席朱海峰先生召集并主持，应出席公司会议的监事 3 人，实际出席公司会议的监 事 3 人。会议召开符合《中华人民共和国公司法》、《公司章程》等规定，会议合 法有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年年度报告的程序符合 法律、行政法规和中国证监会的规定，年报内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 3 票，反对 0 票 ...

证券代码：301101 证券简称：明月镜片 公告编号：2025-002 明月镜片股份有限公司 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届董事会第十七次会议于 2025 年 4 月 16 日在公司会议室以现场结合通讯的表决方式召开。本次会议通知于 2025 年 4 月 4 日以专人送达、电话、微信的方式通知了全体董事。本次会议由董事长谢 公晚先生主持，应出席会议董事 7 人，实际参加会议董事 7 人，公司监事、高级管 理人员列席会议。会议召开符合《中华人民共和国公司法》、《公司章程》等规定， 会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 公司董事会战略与投资委员会和审计委员会审议通过了上述议案。 表决结果：7 票同意；0 票反对；0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的 ...

Financial Performance - The company's operating revenue for 2024 reached ¥770,297,786.61, an increase of 2.88% compared to ¥748,743,207.89 in 2023[18] - Net profit attributable to shareholders for 2024 was ¥176,785,928.28, reflecting a growth of 12.21% from ¥157,543,021.14 in 2023[18] - The basic earnings per share for 2024 was ¥0.8807, up 12.65% from ¥0.7818 in 2023[18] - The total assets at the end of 2024 amounted to ¥1,861,102,531.56, a 6.18% increase from ¥1,752,743,944.92 at the end of 2023[18] - The cash flow from operating activities for 2024 was ¥211,159,110.55, a slight increase of 0.99% from ¥209,092,426.97 in 2023[18] - The company reported a weighted average return on equity of 10.99% for 2024, compared to 10.33% in 2023[18] - The net profit after deducting non-recurring gains and losses for 2024 was ¥152,097,603.69, an increase of 11.67% from ¥136,198,456.01 in 2023[18] - The gross profit margin improved to 58.56%, an increase of 0.98 percentage points compared to the previous year[79] - The sales of the "Easy Control" series products in 2024 amounted to 163.65 million yuan, reflecting a year-on-year growth of 22.7%[79] - The "PMC Ultra Bright" series saw a revenue increase of nearly 45.6% in 2024 compared to the previous year[79] Market Position and Opportunities - The company holds a leading position in the Chinese lens market with a retail market share of 12.4% as of 2024, according to Frost & Sullivan[27] - The number of myopic individuals in China increased from 540 million in 2016 to 660 million in 2020, with the overall myopia rate rising from 39.2% to 47.1%[28] - The government has implemented multiple policies since 2018 to promote myopia prevention and control among children and adolescents, indicating a growing market opportunity for the company[28] - By the end of 2024, the elderly population aged 60 and above in China is projected to reach 310.31 million, accounting for 22% of the total population, driving demand for progressive multifocal lenses[29] - The Chinese eyewear market is projected to grow from CNY 958.3 billion in 2024 to CNY 1,283 billion by 2029, with a CAGR of 5.0% from 2019 to 2024 and 6.0% from 2024 to 2029[30] Product Development and Innovation - The company has developed high-quality lens materials that are 5.6 times more impact-resistant than standard lenses, enhancing user comfort and visual quality[36] - The company launched a new shallow blue light blocking lens product in April 2024, expanding its product matrix to meet diverse user needs[37] - The company’s myopia control lenses utilize proprietary resin materials and unique processes, offering better optical performance and durability compared to competitors[38] - The new generation of "Easy Control PRO2.0" lenses has improved the effective rate of equivalent spherical power to 73.82%, up from 60% in PRO1.0, based on a 12-month clinical trial[39] - The upgraded "1.74" high-index lenses provide a maximum power selection of 1500 degrees, reducing lens thickness and weight for enhanced comfort[39] Sales and Distribution - The company's direct sales revenue reached 442.35 million yuan, accounting for 57.43% of total revenue, while distribution channel revenue was 264.63 million yuan, making up 34.35% of total revenue[55] - The company has established a sales network with 2,707 direct sales clients and 66 distribution clients as of the end of 2024, optimizing its customer structure[55] - Domestic sales accounted for 96.21% of total revenue, with a year-on-year increase of 4.63%[81] Research and Development - The company has 108 R&D personnel, enhancing its research capabilities[78] - R&D expenses rose by 24.96% to 34.99 million yuan, indicating a strong focus on innovation[90] - The company has established partnerships with leading universities and research institutions to develop new technologies and materials[76] - The company is committed to continuous product innovation and aims to launch new products and technologies to create differentiated offerings in the market[141] Corporate Governance and Management - The company operates independently from its controlling shareholders and has a complete business system for supply, production, and sales[154] - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[154] - The company has established independent financial and operational management systems, ensuring no shared bank accounts with controlling shareholders[159] - The company has a well-structured internal management system, with no mixed operations with controlling shareholders[159] Social Responsibility and Brand Building - The company has actively contributed to myopia prevention efforts, including public service campaigns that have aired on national television[58] - The company has partnered with the Chinese Mountaineering Team and the Chinese space program, enhancing its brand recognition and commitment to social responsibility[57] - The company is actively involved in public welfare initiatives to raise awareness about eye health among children and adolescents[125] Future Plans and Strategic Initiatives - Future plans include increased R&D investment in new technologies such as AI smart glasses, focusing on enhancing operational quality[47] - The company plans to expand its product matrix to "1+3+N" by 2025, focusing on the "轻松控 Pro2.0" series and introducing new high-refractive index products[133] - The company aims to enhance brand trust by establishing a team of 100 ophthalmology experts to provide professional endorsement and support[134] Financial Management and Fundraising - The company reported an investment amount of RMB 3,215,000,000 for the current period, representing a 48.43% increase compared to RMB 2,166,000,000 in the same period last year[102] - The total amount of funds raised was RMB 903,783,114, with a net amount of RMB 792,923,877 after deducting various issuance costs[106] - The company has committed to several investment projects, including high-end resin lens production expansion, with a total investment commitment of RMB 30,000,000[109] Employee Development and Training - The total number of employees at the end of the reporting period was 1,068, including 945 at the parent company and 123 at major subsidiaries[185] - The company has established a series of training programs focused on key positions to enhance business and management capabilities[188] - The company has implemented a differentiated salary adjustment strategy for key positions to ensure compensation competitiveness above the industry median[186]

Financial Performance - The company's revenue for Q1 2025 was CNY 197,143,516.30, representing a 2.63% increase compared to CNY 192,086,337.15 in the same period last year[5]. - Net profit attributable to shareholders increased by 11.70% to CNY 47,147,755.44 from CNY 42,208,439.85 year-on-year[5]. - The total operating revenue for the current period is CNY 197,143,516.30, an increase from CNY 192,086,337.15 in the previous period, reflecting a growth of approximately 2.2%[25]. - The company reported a net profit of CNY 51,299,148.60 for the current period, compared to CNY 42,819,783.73 in the previous period, indicating an increase of around 19.8%[25]. - The net profit for the current period is 49,540,791.48, an increase of 11.8% compared to 44,455,356.74 in the previous period[26]. - The total profit for the current period is 56,832,700.50, up from 51,475,060.92, reflecting a growth of 10.5%[26]. - Basic and diluted earnings per share increased to 0.2349 from 0.2103, representing an increase of 11.8%[27]. - The overall business gross margin for Q1 2025 was 58.42%, an increase of 0.35 percentage points compared to the same period last year[16]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 70.63%, amounting to CNY 6,407,779.49 compared to CNY 21,818,792.00 in the previous year[5]. - Cash flow from operating activities generated a net amount of 6,407,779.49, down from 21,818,792.00, indicating a decline of 70.7%[28]. - Cash flow from investing activities resulted in a net outflow of -1,159,560,442.61, worsening from -613,217,427.29 in the previous period[29]. - Cash and cash equivalents decreased to CNY 120,003,686.80 from CNY 1,288,022,229.66, a significant decline of approximately 90.7%[21]. - Cash and cash equivalents at the end of the period decreased to 120,003,686.80 from 481,825,413.16, a decline of 75.1%[29]. - The total assets at the end of the reporting period were CNY 1,945,602,988.04, a 4.54% increase from CNY 1,861,102,531.56 at the end of the previous year[5]. - The total assets increased to CNY 1,945,602,988.04 from CNY 1,861,102,531.56, reflecting a growth of about 4.5%[23]. Liabilities and Expenses - The total liabilities increased to CNY 179,646,168.90 from CNY 144,686,738.94, representing a rise of about 24.2%[23]. - The cash and cash equivalents decreased to CNY 120,003,686.80 from CNY 1,288,022,229.66, a significant decline of approximately 90.7%[21]. - The total operating costs decreased to CNY 145,844,367.70 from CNY 149,266,553.42, representing a reduction of about 2.9%[25]. - The company incurred a tax expense of 7,291,909.02, slightly up from 7,019,704.18, reflecting a rise of 3.9%[26]. Research and Development - Research and development expenses rose by 37.53% to CNY 9,526,927.93 from CNY 6,926,956.54 year-on-year, indicating increased investment in innovation[11]. - Research and development expenses increased to CNY 9,526,927.93 from CNY 6,926,956.54, showing a growth of approximately 37.8%[25]. - The company plans to continue increasing R&D investment to drive product innovation and maintain a competitive edge in the market[19]. Product and Market Development - The company is focusing on developing differentiated products and advancing industry-leading technologies to enhance market competitiveness[19]. - The company launched a series of new high-refractive index products in Q1 2025 to meet diverse consumer needs[18]. - The new 1.67 refractive index added to the PMC Ultra Bright series caters to different myopia levels, enhancing both clarity and aesthetics[18]. - The company is focusing on customized marketing support for top 100 clients to improve brand awareness and customer acquisition efficiency[17]. - The demand for functional and high-refractive index products is increasing among younger consumers, driving innovation in the smart eyewear market[17]. - The company's lens business grew by 5% year-on-year in Q1 2025, excluding the negative impact from overseas and raw material businesses[16]. - Revenue from the PMC Ultra Bright series increased by 44% in Q1 2025, with three star products accounting for 57% of total revenue from regular lenses[16]. - Sales of the "Easy Control" series reached 50.13 million yuan in Q1 2025, representing a year-on-year growth of 22.1%[16]. - The "Easy Control" series sales for 2024 are projected to reach 54.96 million yuan, reflecting a year-on-year growth of 33.8%[16]. - The company aims to provide comprehensive eye health solutions by continuously optimizing product performance and service quality[17]. Accounts Receivable - The company reported a significant increase in accounts receivable by 59.27%, reaching CNY 173,839,579.72, attributed to increased sales and outstanding credit sales[11]. Borrowings - The company has undertaken a special loan, resulting in a 100% increase in long-term borrowings to CNY 26,876,509.71[11]. Other Income - The company recorded a total of CNY 5,571,395.96 in non-recurring gains, primarily from government subsidies and financial asset disposals[7]. Cash Flow from Investment Activities - The company experienced a 89.09% increase in net cash flow from investment activities, amounting to CNY -1,159,560,442.61, due to changes in investment product terms[11].